PAHC trades 17.9% above Wall Street's consensus target of $28.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PAHC achieves its forward estimates and maintains a stable P/E multiple of 11.1x. This scenario reflects the blended consensus of 14 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Phibro Animal Health Corporation (PAHC) has a Wall Street consensus price target of $28.00, based on estimates from 14 covering analysts. With the stock currently trading at $34.10, this represents a potential downside of -17.9%. The company has a market capitalization of $1.38B.
Analyst price targets range from a low of $17.00 to a high of $49.00, representing a 114% spread in expectations. The median target of $18.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, PAHC trades at a trailing P/E of 28.7x and forward P/E of 11.1x. The forward PEG ratio of 1.48 indicates reasonable valuation for growth. Analysts expect EPS to grow +26.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $52.76, with bear and bull scenarios of $33.24 and $69.52 respectively. Model confidence stands at 43/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ELANElanco Animal Health Incorporated | $11.3B | $22.58 | $28.00 | +24.0% | Buy | 19.9x | 21 |
 ZTSZoetis Inc. | $30.0B | $71.63 | $87.33 | +21.9% | Hold | 11.5x | 32 |
 NEOGNeogen Corporation | $3.0B | $13.57 | $13.00 | -4.2% | Buy | 43.8x | 11 |
 IDXXIDEXX Laboratories, Inc. | $41.2B | $522.02 | $665.00 | +27.4% | Buy | 35.3x | 23 |
 TSNTyson Foods, Inc. | $18.2B | $51.36 | $67.40 | +31.2% | Buy | 14.2x | 30 |
 HRLHormel Foods Corporation | $11.0B | $19.91 | $24.67 | +23.9% | Hold | 13.4x | 30 |
 PPCPilgrim's Pride Corporation | $6.6B | $27.63 | $36.67 | +32.7% | Hold | 11.6x | 22 |
 CAGConagra Brands, Inc. | $7.1B | $14.78 | $13.95 | -5.6% | Hold | 8.7x | 25 |
 DEDeere & Company | $191.5B | $709.48 | $731.20 | +3.1% | Buy | 39.2x | 46 |
 CTVACorteva, Inc. | $53.8B | $80.45 | $95.22 | +18.4% | Buy | 21.4x | 37 |
Quick answers to the most common questions about buying PAHC stock.
PAHC's consensus price target is $28, -17.9% below the current price of $34.1. The 14 analysts tracking PAHC see downside risk at present valuations.
PAHC has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $28 implies -17.9% downside from current levels.
With a forward P/E of 11.0927x, PAHC trades at a relatively low valuation. The consensus target of $28 implies -17.9% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $49 for PAHC, while the most conservative target is $17. The consensus of $28 represents the median expectation. Our quantitative valuation model projects a bull case target of $70 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
PAHC is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 4 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PAHC stock forecast based on 14 Wall Street analysts shows a consensus price target of $28, with estimates ranging from $17 (bear case) to $49 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $53, with bear/bull scenarios of $33/$70.
Our quantitative valuation model calculates PAHC's fair value at $53 (base case), with a bear case of $33 and bull case of $70. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 43/100.
PAHC trades at a forward P/E ratio of 11.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 28.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on PAHC, with 4 Sell ratings and a price target of $28 (-17.9% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PAHC analyst price targets range from $17 to $49, a 114% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $28 consensus represents the middle ground. Our model's $33-$70 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.